CVR Partners, LP (UAN): Among Most Expensive Stocks Insiders Are Buying After Trump's Tariff Rollout
We recently published a list of . In this article, we are going to take a look at where CVR Partners, LP (NYSE:UAN) stands against other most expensive stocks insiders are buying after Trump's tariff rollout.
Wall Street banks have sharply cut their targets for the broader market index due to growing fears about the economic fallout from new tariffs, writes the Financial Times. Since the tariff announcement on April 2, the broader market index has dropped nearly 7%. Major banks now expect lower market gains in 2025, with some analysts predicting a possible bear market directly triggered by presidential policy shifts.
Amid tariff wars and market uncertainty, insider trading often draws attention. Insider stock purchases may signal executive confidence, while sales aren't necessarily negative—they could reflect personal or diversification choices. It's best to view insider trading in context with a company's financials and market conditions.
Today, we're highlighting most expensive stocks that insiders have been buying in April. Using Insider Monkey's trading screener, we looked for companies with share prices of at least $30 and insider purchases between April 2 and April 21. From there, we ranked the top 12 stocks based on the highest average purchase price per share.
Stocks that were recently covered were excluded from this list. Most of those can be seen on this list of the 19 mid- and large-cap stocks insiders are buying after Trump's tariff rollout.
Our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds, focusing on insider trading and stock picks from hedge fund investor newsletters and conferences. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points ().
A farmer in traditional attire inspecting a field of nitrogen fertilized crops.
CVR Partners, LP (NYSE:UAN) produces and sells nitrogen fertilizers, including ammonia and urea ammonium nitrate, primarily in the U.S. The company serves both agricultural and industrial customers. It is based in Sugar Land, Texas, and is a subsidiary of CVR Energy, Inc. While ranking sixth among the 12 most expensive stocks insiders are buying after Trump's Tarrif Rollout, it is also one of the 15 stocks that received the most insider investment in March.
In April, one insider and a large shareholder at CVR Partners (NYSE:UAN), Billionaire Carl Icahn, purchased $3.86 million worth of shares at an average price of $71.05 per share. The stock has declined 2% since the beginning of the year, trading at $71.05 per share. Over the past 12 months, its shares dropped 1.71%.
In 2024, CVR Energy reported revenue of $7.61 billion, down 17.7% from the previous year's $9.25 billion. Net income dropped to $7 million, or 6 cents per share, compared to $769 million, or $7.65 per share in 2023. The company also posted an adjusted loss of 51 cents per share, down from adjusted earnings of $5.64 per share in 2023.
Overall, UAN ranks 6th on our list of most expensive stocks insiders are buying after Trump's tariff rollout. While we acknowledge the potential of UAN, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than UAN but that trades at less than 5 times its earnings, check out our report about this .
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
Cardinal Health Insiders Sell US$18m Of Stock, Possibly Signalling Caution
In the last year, many Cardinal Health, Inc. (NYSE:CAH) insiders sold a substantial stake in the company which may have sparked shareholders' attention. When analyzing insider transactions, it is usually more valuable to know whether insiders are buying versus knowing if they are selling, as the latter sends an ambiguous message. However, shareholders should take a deeper look if several insiders are selling stock over a specific time period. While insider transactions are not the most important thing when it comes to long-term investing, we would consider it foolish to ignore insider transactions altogether. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. The CEO & Director, Jason Hollar, made the biggest insider sale in the last 12 months. That single transaction was for US$8.0m worth of shares at a price of US$109 each. That means that an insider was selling shares at slightly below the current price (US$161). We generally consider it a negative if insiders have been selling, especially if they did so below the current price, because it implies that they considered a lower price to be reasonable. Please do note, however, that sellers may have a variety of reasons for selling, so we don't know for sure what they think of the stock price. We note that the biggest single sale was only 46% of Jason Hollar's holding. Cardinal Health insiders didn't buy any shares over the last year. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date! View our latest analysis for Cardinal Health I will like Cardinal Health better if I see some big insider buys. While we wait, check out this free list of undervalued and small cap stocks with considerable, recent, insider buying. Many investors like to check how much of a company is owned by insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Cardinal Health insiders own about US$146m worth of shares (which is 0.4% of the company). I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders. The fact that there have been no Cardinal Health insider transactions recently certainly doesn't bother us. It's great to see high levels of insider ownership, but looking back over the last year, we don't gain confidence from the Cardinal Health insiders selling. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. At Simply Wall St, we found 1 warning sign for Cardinal Health that deserve your attention before buying any shares. If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
36 minutes ago
- Yahoo
Why HCA Healthcare, Inc. (NYSE:HCA) Could Be Worth Watching
Today we're going to take a look at the well-established HCA Healthcare, Inc. (NYSE:HCA). The company's stock saw a decent share price growth of 19% on the NYSE over the last few months. Shareholders may appreciate the recent price jump, but the company still has a way to go before reaching its yearly highs again. With many analysts covering the large-cap stock, we may expect any price-sensitive announcements have already been factored into the stock's share price. However, could the stock still be trading at a relatively cheap price? Let's examine HCA Healthcare's valuation and outlook in more detail to determine if there's still a bargain opportunity. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. Good news, investors! HCA Healthcare is still a bargain right now according to our price multiple model, which compares the company's price-to-earnings ratio to the industry average. In this instance, we've used the price-to-earnings (PE) ratio given that there is not enough information to reliably forecast the stock's cash flows. we find that HCA Healthcare's ratio of 15.45x is below its peer average of 20.5x, which indicates the stock is trading at a lower price compared to the Healthcare industry. Although, there may be another chance to buy again in the future. This is because HCA Healthcare's beta (a measure of share price volatility) is high, meaning its price movements will be exaggerated relative to the rest of the market. If the market is bearish, the company's shares will likely fall by more than the rest of the market, providing a prime buying opportunity. See our latest analysis for HCA Healthcare Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Buying a great company with a robust outlook at a cheap price is always a good investment, so let's also take a look at the company's future expectations. HCA Healthcare's earnings over the next few years are expected to increase by 23%, indicating a highly optimistic future ahead. This should lead to more robust cash flows, feeding into a higher share value. Are you a shareholder? Since HCA is currently below the industry PE ratio, it may be a great time to increase your holdings in the stock. With a positive outlook on the horizon, it seems like this growth has not yet been fully factored into the share price. However, there are also other factors such as financial health to consider, which could explain the current price multiple. Are you a potential investor? If you've been keeping an eye on HCA for a while, now might be the time to make a leap. Its buoyant future profit outlook isn't fully reflected in the current share price yet, which means it's not too late to buy HCA. But before you make any investment decisions, consider other factors such as the track record of its management team, in order to make a well-informed assessment. So if you'd like to dive deeper into this stock, it's crucial to consider any risks it's facing. Our analysis shows 3 warning signs for HCA Healthcare (1 is a bit concerning!) and we strongly recommend you look at these before investing. If you are no longer interested in HCA Healthcare, you can use our free platform to see our list of over 50 other stocks with a high growth potential. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Miami Herald
39 minutes ago
- Miami Herald
The 10 most popular new cars & SUVs of 2025 (so far), according to Consumer Reports
Looming economic uncertainties, stubbornly high interest rates, and Trump's tariffs on imported auto parts and automobiles might lead you to think that 2025 is the worst time ever to buy a new car. But 3.9 million new vehicles were sold in the first few months of the year, which represented a 4% increase over 2024. And while current economic headwinds have caused Cox Automotive to reduce its full-year new vehicle sales estimates from 16.3 million to 15.6 million, that still means millions of people are heading over to their dealerships to purchase a new car or SUV. Because the simple fact is, if you need a new car, you need a new car. Don't miss the move: Subscribe to TheStreet's free daily newsletter Buying a new vehicle seems to be an increasingly smart investment, due to the fact that used cars aren't the steals they used to be. Their prices have also been on the rise: According to data from Edmunds, the average price of a three-year-old vehicle is now an incredible $30,522, which significantly narrows the cost differential between new and used vehicles. There are plenty of advantages to buying a new vehicle, with safety and reliability at the top of the list. Related: The 10 most reliable car brands in 2025 according to Consumer Reports New cars are safer Due to advancements in safety technologies and structural designs, new cars typically have more standard safety features than used vehicles. These days, automatic emergency braking (AEB) comes standard on most new vehicles, while blind-spot monitoring and rear cross-traffic warning systems are other common new-vehicle features that can often help to prevent accidents from occurring in the first place. New cars are more reliable In addition, shiny new cars come with shiny new components, lessening the chance of immediate mechanical issues. They also have the added benefit of a factory warranty, which covers repairs for a certain period-something older, pre-owned vehicles might not. Consumer Reports (CR), the venerable product testing and consumer advocacy organization, has been in business since 1936, which means it has weathered economic ups and downs for 89 years. In fact, its entire purpose, which is to provide unbiased reviews of tens of thousands of products in order to inform consumers on product quality and safety, was shaped by the harsh economic realities of the Great Depression. Related: The 10 best compact crossover SUVs according to Consumer Reports Acknowledging the challenges car buyers face in 2025, CR put together a few helpful hints for consumers so they can avoid overpaying for their vehicles. They include: Avoid buying first-year "redesigned" models, which have received plenty of media hype and, often, a steep price tag to match. Instead, CR suggests waiting another year so that the vehicles' inflated sticker price comes down-and any "kinks" the new model experiences have been worked out, consumers should select smaller vehicles, or ones with fewer features, simply due to the fact that they have lower material and manufacturing costs. Because smaller vehicles weigh less, they also experience lower destination charges, which get passed on to the consumer. CR suggests that car buyers do their research online and find out what prices cars in their area are selling for, as well as what their MSRP is. That can help you determine a vehicle's true value-as well as how much you're willing to spend to get it. Consumer Reports listens to the feedback it receives from its 6 million members; in fact, it takes into account which cars and SUVs consumers are searching for online when it compiles its list of "most popular" vehicles. More on Consumer Reports: The best gas grills under $250, ranked by Consumer Reports dataThe least expensive car brands to repair & maintain according to Consumer ReportsTop 10 electric cars that aren't Tesla, based on Consumer Reports data But the venerable consumer advocacy group doesn't stop at data. It then cross references these vehicles with results from its own, extensive internal tests in order to rank its list in order of highest-rated vehicles. This helps consumers to know they're making the smartest possible buying decision-no matter what's going on in the world at large. CR road-tests dozens of vehicles at its testing facility in Colchester, Connecticut, putting each car and SUV through a barrage of tests, including acceleration, braking, crash testing, emergency handling, smoothness of ride, and fuel economy, to name a few. It then surveys its members on metrics such as reliability and overall satisfaction, combining all results together into its Overall Score. CR notes that each of the vehicles on its list of "Most Popular New Cars and SUVs" have received high Overall Scores. And, all of these vehicles are categorized as SUVs. However, while all of the vehicles that made its list come with standard automatic emergency braking (AEB), it notes which ones also come with blind-spot monitoring and rear cross-traffic warning systems. Here's the list: 2025 Subaru Forester MPG: Overall 29 / Hwy 39 Price: $29,995–$43,295 2025 Toyota RAV4 MPG: Overall 27 / Hwy 38Price: $29,250–$40,605 2025 Honda CR-V MPG: Overall 26 / Hwy 33Price: $30,100–$50,000 OWS Photography, CC BY 4.0, via Wikimedia Commons 2025 Subaru Crosstrek MPG: Overall 29 / Hwy 41 Price: $26,560–$33,360 2025 Toyota RAV4 Hybrid MPG: Overall 37 / Hwy 41 Price: $28,850–$40,205 Ethan Llamas, CC BY-SA 4.0, via Wikimedia Commons 2025 Mazda CX-5 MPG: Overall 24 / Hwy 33 Price: $28,770–$40,800 2025 Honda CR-V Hybrid MPG: Overall 35 / Hwy 38 Price: $34,650–$41,100 2025 Toyota Highlander MPG: Overall 22 / Hwy 33 Price: $39,820–$53,975 2025 Toyota Highlander Hybrid MPG: Overall 35 / Hwy 41 Price: $39,520–$53,675 Related: 8 popular vehicles that are less reliable than you think, according to Consumer Reports The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
